Physician profile
Saeed Hamid
NPI 1275660763
$10,110.04
in general payments reported to CMS, 2019-2025
24 companies · $3,741 in 2025
The $3,741 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,208 · 2020: $651 · 2021: $828 · 2022: $764 · 2023: $1,324 · 2024: $1,593 · 2025: $3,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,584 · Consulting Fee: $2,070 · Education: $3.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,584.49 |
| Consulting Fee | $2,070.00 |
| Education | $3.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,310.51 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,249.66 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,172.88 | 2019-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $838.20 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $830.11 | 2021-2025 | |
| Axsome Therapeutics, INC. | $570.79 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $531.98 | 2019-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $489.85 | 2019-2025 | Rexulti |
| Allergan, INC. | $474.24 | 2019-2020 | |
| Indivior INC. | $447.06 | 2019-2025 | Sublocade, Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $434.41 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $193.40 | 2020-2025 | Invega Sustenna, Spravato, Invega |
| Sunovion Pharmaceuticals INC. | $144.98 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $89.05 | 2019-2025 | Uzedy |
| Neuronetics, INC. | $86.62 | 2019-2024 | Neurostar Tms Therapy System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $85.02 | 2019-2024 | Ingrezza |
| Orexo US, INC. | $29.51 | 2022 | |
| Shire North American Group INC | $27.37 | 2019 | |
| Noven Therapeutics, LLC | $21.76 | 2025 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $20.96 | 2023 | Quviviq |
| Uswm, LLC | $18.34 | 2022 | |
| Braeburn INC. | $14.83 | 2025 | Brixadi |
| Eisai INC. | $14.28 | 2022 | |
| Corium, LLC | $14.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saeed Hamid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.